NCT07685808ClinicalTrials.gov
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
A Phase 2, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, With Different Doses and Drug-Titration Algorithms in Participants Living With Overweight or Obesity
In brief
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing…
Phase 2360 participants sought22 sites1 country
Categories
Registered in 1 registry
- ClinicalTrials.govNCT07685808Open this record at ClinicalTrials.govSynced 2 days ago
One study can be registered in several registries. We show it once and link every record we hold.
Trial information is shown as published by the registry, in its original language.
Interested in this study?
Sign in or create an account to register your interest and follow this study.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-07-06; recorded start 2026-07-28
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 264 other studies in this databaseCounted from the lead sponsor named in the record (Regeneron Pharmaceuticals)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre0/8
Single site, or site count not stated
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study: 360 participants (target), run at 22 sites.
How this score is built
- Enrolment25/40
360 participants (target)
- Site count0/25
Site count not stated in the record
- Country count0/15
Country count not stated in the record
- Planned duration6/10
Planned over about 18 months
- Sponsor scale9/10
Regeneron Pharmaceuticals has led 250 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Summary
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much study drug is in the blood at different times * How well the study drug works * What effects the study drug may have on the body at different dosing schedules * If the body makes antibodies to the study drug as this may cause the study drug to not work as well
Conditions
- Overweight or Obesity
Eligibility
| Sex | All |
|---|---|
| Ages | 18 Years – No maximum |
| Healthy volunteers | No |
Eligibility as written in the registry
Eligibility in plain statements
This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.
Study design
| Study type | Interventional |
|---|---|
| Phase | Phase 2 |
| Allocation | Randomised |
| Intervention model | PARALLEL |
| Primary purpose | TREATMENT |
| Masking | QUADRUPLE (4) |
| Enrolment | 360 participants sought |
Sponsor and collaborators
- Regeneron Pharmaceuticals Sponsor
Arms and interventions
- Olatorepatide arm 1EXPERIMENTAL
- Olatorepatide arm 2EXPERIMENTAL
- Olatorepatide arm 3EXPERIMENTAL
- Olatorepatide arm 4EXPERIMENTAL
- Olatorepatide arm 5EXPERIMENTAL
- Matching Placebo arm 6ACTIVE_COMPARATOR
Interventions
- Drug Olatorepatide
Administered per the protocol
- Drug Placebo
Administered per the protocol
Outcome measures
Primary outcome
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Time frame Up to approximately 60 weeks
Primary outcome
Severity of TEAEs
Time frame Up to approximately 60 weeks
Primary outcome
Percent change in body weight
Time frame From baseline to week 52
Secondary outcome
Olatorepatide concentrations
Time frame Up to approximately 60 weeks
Secondary outcome
Occurrence of Anti-Drug Antibody (ADA) to olatorepatide
Time frame Up to approximately 52 weeks
Secondary outcome
Magnitude of ADA to olatorepatide
Time frame Up to approximately 52 weeks
Dates
| Start date | July 28, 2026 (actual) |
|---|---|
| Primary completion | January 21, 2028 (estimated) |
| Completion | January 21, 2028 (estimated) |
| First posted | July 6, 2026 (actual) |
| Last updated | November 18, 2026 |
| Results posted | Not stated in the registry record |
| Status last verified | November 2026 |
Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.
Locations
22 sites are recruiting
United States
| Facility | City | State or region | Status |
|---|---|---|---|
| Flourish Research, Ravenswood Rheumatology | Chicago | Illinois | Recruiting |
| Charter Research LLC - Chicago | Chicago | Illinois | Recruiting |
| Alliance for Multispecialty Research (AMR) Clinical Miami | Doral | Florida | Recruiting |
| AMR Clinical - Fort Myers | Fort Myers | Florida | Recruiting |
| Tribe Clinical Research | Greenville | South Carolina | Recruiting |
| AGA Clinical Trials | Hialeah | Florida | Recruiting |
| Flourish Research, Nature Coast Clinical Research | Inverness | Florida | Recruiting |
| Flourish Research, Jacksonville Center for Clinical Research | Jacksonville | Florida | Recruiting |
| AMR Clinical - Lexington | Lexington | Kentucky | Recruiting |
| K2 Medical Research Maitland LLC, Main Office | Maitland | Florida | Recruiting |
| AMR Clinical - Mobile | Mobile | Alabama | Recruiting |
| NYC Research Inc | New York | New York | Recruiting |
| AMR Clinical - Chicago Oak Brook | Oak Brook | Illinois | Recruiting |
| Velocity Clinical Research - Omaha | Omaha | Nebraska | Recruiting |
| Rochester Clinical Research | Rochester | New York | Recruiting |
| Flourish Research, Legacy Oaks Tower | San Antonio | Texas | Recruiting |
| The IMA Group, IMA Clinical Research St. Petersburg | St. Petersburg | Florida | Recruiting |
| Charter Research LLC - The Villages | The Villages | Florida | Recruiting |
| Diablo Clinical Research - Flourish Research | Walnut Creek | California | Recruiting |
| Chase Medical Research | Waterbury | Connecticut | Recruiting |
| AMR Clinical Wichita | Wichita | Kansas | Recruiting |
| Clinical Site Partners, LLC DBA Flourish Research | Winter Park | Florida | Recruiting |
Study documents
No documents are linked in this registry record.
Changes over time
- November 18, 2026
Site added
1 site added (22 total)
2122
- October 13, 2026
Site added
3 sites added (21 total)
1821
- September 29, 2026
Site added
13 sites added (18 total)
518
- August 20, 2026
Status changed
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- August 20, 2026
Recruitment opened
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- August 20, 2026
Site added
5 sites added (5 total)
05